The RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Sjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Checkpoint Inhibitors Causing Rheumatic Disease
Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.
The RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Biosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists.
The RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Crohn's Arthritis Linked to E. Coli Infection
Articular manifestations of Crohn's disease affects a significant number of patients with either oligoarticular or RA-like polyarthritis or spondyloarthritis.
The RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
